tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

H.C. Wainwright downgrades MiNK Therapeutics after 400% rally

H.C. Wainwright downgraded MiNK Therapeutics (INKT) to Neutral from Buy with an unchanged price target of $35 after the company announced that a publication discussing the mechanism of action of CAR-iNKT cells was published in Frontiers in Immunology. With the shares up over 400% since last week, the “majority of the enthusiasm has been priced in for the near-term,” the analyst tells investors in a research note. As a result, H.C. Wainwright downgraded MiNK on valuation, It looks to additional updates from the agenT-797 Phase 2 gastric trial in the upcoming months to reevaluate the stock’s thesis.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1